Contact this trialFirst, we need to learn more about you.
SGLT2 Inhibitor
Sotagliflozin for Type 1 Diabetes
Recruiting1 awardPhase 3
Stanford, California
This trial aims to test the effects of a new drug called SOTA on kidney function in people with type 1 diabetes and moderate to advanced kidney disease. Previous studies have shown that SOTA can increase
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.